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Guest Editorial
Journal of Urology June, 2012
“The Quest for the Perfect Prostate Biopsy Continues"
Leonard G. Gomella, MD, FACS
Chairman, Department of Urology
Thomas Jefferson University
Kimmel Cancer Center
1025 Walnut Street, 1102
Philadelphia, PA 19107
215-955-1702/215-923-1884 (fax)
Until well into the 1980's, biopsy of the prostate often relied on a few cores using
a device such as the Vim-Silverman needle digitally guided either transperineally or transrectally into a palpably abnormal prostate. In this pre-PSA era,
prostate cancers were often detected at an advanced clinical stage. The
modern era of prostate biopsy was ushered in the late 1980's with the
development of the spring loaded biopsy needle and the trans-rectal
ultrasound (TRUS) probe. Since that time, the state of the art has evolved from
the TRUS directed biopsy of suspicious lesions, to the sextant and now extended
10-12 core biopsy schema using local anesthesia. The decision to perform
prostate biopsy today is often based on the interpretation of changes in serum
PSA, leading to cancer detection in palpably normal prostate glands.
Our current "gold standard" prostate biopsy is based on standard gray scale
TRUS imaging. Although early investigations suggested that prostate cancer is
seen as a "hypoechoic lesion" on TRUS, the reality today is that most PSA
detected cancers have a highly variable appearance. These cancers do not
demonstrate any unique characteristics on gray scale imaging. While a
sonographically distinct lesion is biopsied when seen, distinguishing benign from
malignant tissue with standard ultrasound is challenging. (1) Standard gray scale
TRUS is very effective at providing an accurate size determination as well as
guiding the biopsy needle ensuring an adequate sampling of the various
regions of the gland. It usually falls short in the detection of all prostate cancers
that may be present due to the common small and multifocal nature of the
disease.
Changes in the management of prostate cancer require a much more careful
assessment of the prostate cancer than ever. No longer is it appropriate to
identify simply the largest or index tumor and make a simple diagnosis of
prostate cancer. Standard and evolving approaches, such as active
surveillance and focal therapy, ideally require that all lesions within the prostate
be detected and characterized to determine the appropriate course of action.

Multifocality is the rule rather than the exception and identifying the tumor with
the aggressive phenotype can no longer be made based on size alone. Using a
saturation biopsy approach with 20 or more cores, may not be appropriate for
the initial biopsy but has utility in the repeat biopsy setting. (2)
Many imaging technologies have been studied to improve the biopsy yield.
Color Doppler ultrasound enhanced prostate biopsy has limitations but when
combined with microbubble contrast agents, improvements are seen. Work at
our Jefferson Prostate Diagnostic center and by others has demonstrated that
hypervascular prostate cancers can be detected with fewer biopsy cores using
microbubble contrast-enhanced ultrasound (CEUS). Most significantly, cancers
with higher Gleason grades cancers are more likely to be detected with CEUS
when compared to other TRUS approaches. (1,3) Even with this improvement in
the detection of higher grade cancers, systematic biopsies are still required with
these techniques to optimize the detection of prostate cancer. Several papers
in this issue of the Journal of Urology address prostate biopsy and tumor
detection.
Elastography, also known as elastosonography, represents a newer TRUS based
technique that relies on alterations in tissue stiffness that may indicate the
presence of prostate cancer. In our Jefferson Prostate Diagnostic Center's initial
elastography experience, areas identified in the prostate with an abnormal
elastography pattern were twice as likely to be prostate cancer when
compared to biopsies in areas of normal elasticity. (4) Using real time
elastography, Brock and associates also noted a higher biopsy yield, but in
similar fashion to the CEUS experience previously cited, it was not sensitive
enough to omit the systematic biopsies. (5)
MRI has enjoyed a significant growth in the management of prostate cancer
with improvements in the multi parametric MRI such as higher power scanners
and newer imaging protocols. Although very cumbersome, MRI directed
biopsies are performed at selected centers. In spite of the enthusiasm for more
complete detection of all prostate lesions by MRI, Rosenkrantz and associates
note that many tumors are not detected by these MRI techniques and suggest
the further study of the missed tumors be used to improve MRI imaging (6).
Fusion of MRI with TRUS imaging and biopsy is a promising approach to gain the
benefits of both technologies. (7)
A potential advantage of MRI is in the identification of anteriorly located tumors
that may escape a transrectal needle biopsy approach. Huo and associates
report on their experience with initial transperineal template biopsy. (8) The
transperineal approach potentially allows a more complete biopsy of the
prostate including the anterior zone. They note only a fair pathologic

agreement with the final radical prostatectomy specimens and suggest larger
prostates require more biopsies using this approach.
While the short term risks of prostate biopsy are well known, little data is available
on the long term implications of repeat transrectal biopsy on cancer outcomes.
It is reassuring that in the era of active surveillance with mandated repeat
prostate biopsies, in a cohort analysis of over 2700 men in the SEARCH database
a repeat prostate biopsy did not demonstrate an increased risk of biochemical
recurrence following radical prostatectomy. (9)
Our current biopsy methods adequately identify larger non-palpable lesions. As
we move to earlier detection of prostate cancer, the lesions become smaller
and more difficult to detect by our standard biopsy and imaging techniques.
Some argue that these smaller lesions are clinically insignificant and of no
clinical consequence. This adds fuel to the ongoing prostate cancer screening
controversy by causing detection and overtreatment of small cancers that will
never harm the patient. (10) However, these smaller lesions may exhibit
characteristics of clinically aggressive disease regardless of size and may impact
treatment decisions particularly in men with long life expectancies. In our quest
for the perfect prostate biopsy, identifying lesions by needle biopsy or imaging
may not be enough. Methods to more precisely discriminate aggressive
prostate cancer from indolent disease should also be a part of our biopsy efforts
going forward.
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